(0.29%) 5 114.96 points
(0.30%) 38 353 points
(0.34%) 15 983 points
(-0.95%) $83.05
(5.36%) $2.03
(0.30%) $2 354.20
(0.56%) $27.69
(4.29%) $961.70
(-0.26%) $0.932
(-0.43%) $10.98
(-0.58%) $0.796
(1.63%) $93.37
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.24%
@ $25.39
発行日: 15 2月 2024 @ 05:49
リターン: -19.69%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: 3.63 %
Live Chart Being Loaded With Signals
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis...
Stats | |
---|---|
本日の出来高 | 190 837 |
平均出来高 | 676 840 |
時価総額 | 1.53B |
EPS | $0 ( 2024-02-22 ) |
次の収益日 | ( $-0.190 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -19.99 |
ATR14 | $0.0200 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Eastham Karin | Buy | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Stock Option (right to buy) |
2024-03-15 | Chambers Rebecca | Buy | 4 318 | Common Stock |
2024-03-15 | Chambers Rebecca | Sell | 2 189 | Common Stock |
INSIDER POWER |
---|
32.58 |
Last 99 transactions |
Buy: 1 146 076 | Sell: 688 515 |
ボリューム 相関
Veracyte Inc 相関
10 最も負の相関 | |
---|---|
RMRM | -0.957 |
APOP | -0.906 |
FEYE | -0.895 |
GAINL | -0.885 |
SVAC | -0.885 |
SVOK | -0.868 |
TLGT | -0.867 |
TDAC | -0.853 |
PAIC | -0.851 |
CMLF | -0.846 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Veracyte Inc 相関 - 通貨/商品
Veracyte Inc 財務諸表
Annual | 2023 |
収益: | $361.05M |
総利益: | $223.15M (61.81 %) |
EPS: | $-1.020 |
FY | 2023 |
収益: | $361.05M |
総利益: | $223.15M (61.81 %) |
EPS: | $-1.020 |
FY | 2022 |
収益: | $296.54M |
総利益: | $194.95M (65.74 %) |
EPS: | $-0.510 |
FY | 2021 |
収益: | $219.51M |
総利益: | $145.11M (66.11 %) |
EPS: | $-1.419 |
Financial Reports:
No articles found.
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。